• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

1.720 -0.240 (-12.25%)
Streaming Delayed Price Updated: 2:23 PM EST, Mar 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,195,193
Open 1.940
Bid (Size) 1.710 (10,100)
Ask (Size) 1.720 (20,200)
Prev. Close 1.960
Today's Range 1.700 - 1.960
52wk Range 0.5150 - 2.000
Shares Outstanding 257,328,085
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Ocugen (OCGN) Q4 2025 Earnings Call Transcript ↗
March 04, 2026
Ocugen (OCGN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Ocugen Inc (NASDAQ:OCGN) Stock Drops 7% on Q4 Revenue Miss, Highlights Clinical Pipeline ↗
March 04, 2026
Via Chartmill

Performance

YTD
+24.6%
+24.6%
1 Month
+20.3%
+20.3%
3 Month
+42.1%
+42.1%
6 Month
+63.8%
+63.8%
1 Year
+191.5%
+191.5%

More News

Read More
News headline image
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
March 04, 2026
From Ocugen
Via GlobeNewswire
News headline image
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
March 03, 2026
Via FinancialNewsMedia
News headline image
Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
January 09, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
December 10, 2025
From Ocugen
Via GlobeNewswire
News headline image
Earnings Scheduled For November 5, 2025 ↗
November 05, 2025
Via Benzinga
News headline image
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
March 02, 2026
From Ocugen
Via GlobeNewswire
News headline image
Why Did OCGN Stock Rise Today? ↗
February 25, 2026
Via Stocktwits
News headline image
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
February 18, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
February 09, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
January 23, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
January 21, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Stock Is Surging Today: What's Driving The Action? ↗
January 16, 2026
Via Benzinga
News headline image
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
January 15, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
January 13, 2026
From Ocugen
Via GlobeNewswire
News headline image
OCGN Stock Rises Pre-Market After Gene Therapy Data Shows Promise In Rare Eye Disorder ↗
January 12, 2026
Via Stocktwits
News headline image
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
January 12, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference
November 20, 2025
From Ocugen
Via GlobeNewswire
News headline image
Ocugen (OCGN) Q3 2025 Earnings Call Transcript ↗
November 05, 2025
Via The Motley Fool
Topics Earnings
News headline image
OCUGEN INC (NASDAQ:OCGN) Reports Mixed Q3 2025 Results Amid Clinical Pipeline Progress ↗
November 05, 2025
Via Chartmill
News headline image
Ocugen Provides Business Update with Third Quarter 2025 Financial Results
November 05, 2025
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results
October 23, 2025
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Present at Industry and Investor Conferences in October 2025
October 02, 2025
From Ocugen
Via GlobeNewswire
News headline image
Forecasting The Future: 4 Analyst Projections For Ocugen ↗
September 19, 2025
Via Benzinga

Frequently Asked Questions

Is Ocugen, Inc. - Common Stock publicly traded?
Yes, Ocugen, Inc. - Common Stock is publicly traded.
What exchange does Ocugen, Inc. - Common Stock trade on?
Ocugen, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ocugen, Inc. - Common Stock?
The ticker symbol for Ocugen, Inc. - Common Stock is OCGN on the Nasdaq Stock Market
What is the current price of Ocugen, Inc. - Common Stock?
The current price of Ocugen, Inc. - Common Stock is 1.720
When was Ocugen, Inc. - Common Stock last traded?
The last trade of Ocugen, Inc. - Common Stock was at 03/05/26 02:23 PM ET
What is the market capitalization of Ocugen, Inc. - Common Stock?
The market capitalization of Ocugen, Inc. - Common Stock is 442.58M
How many shares of Ocugen, Inc. - Common Stock are outstanding?
Ocugen, Inc. - Common Stock has 443M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap